Viridian Therapeutics reports positive VRDN-008 phase 1 results supporting potential every-eight-week dosing
VRDN•Viridian Therapeutics reported positive phase 1 results for VRDN-008, supporting potential subcutaneous dosing every eight weeks. The healthy-volunteer trial showed deep, sustained IgG suppression, generally favorable tolerability, and no serious adverse events or dose-limiting toxicities.
1. Phase 1 results
Viridian Therapeutics said its healthy-volunteer phase 1 trial of VRDN-008 showed deep, sustained IgG suppression with generally favorable tolerability and no serious adverse events or dose-limiting toxicities. The results support potential subcutaneous dosing every eight weeks.
2. Planned MG trial
A registrational trial in MG is planned for mid-2027, pending regulatory feedback. It would compare dosing every four or eight weeks against placebo, using the enFuse on-body injector.
